135
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected

, , , , , , & show all
Pages 1657-1663 | Received 20 Sep 2020, Accepted 26 Jan 2021, Published online: 13 Feb 2021
 

Abstract

EBV is the most prevalent cause of infection-associated hemophagocytic lymphohistiocytosis (IAHLH), non-EBV IAHLH is observed clinically but less documented. We conducted a retrospective research enrolled 36 cases from 1/1/2015 to 31/12/2019. Intriguingly, 92% cases were immunocompetent individuals prior to the onset of HLH. Clinically, the cardinal features were prolonged high fever, splenomegaly and hemophagocytosis. Bicytopenia occurred in most patients, besides, liver dysfunction was characterized by increased transaminase, bilirubin, alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (γ-GGT) and lactate dehydrogenase (LDH). Immunomodulatory agents should be added to control the overwhelming inflammatory storm without delay. Once a certain pathogen was identified as the causative factor of HLH, cytotoxic agents were withdrawn, specific pathogen-directed treatment was initiated. Further, glucocorticoids were tapered off when a stable state of HLH was achieved. After treatment, about 70% patients were fully recovered without relapse. All in all, non-EBV IAHLH is a special group of HLH with admirable outcome.

Acknowledgements

The authors would like to thank all the doctors and nurses in the Department of Hematology in Beijing Friendship Hospital, Capital Medical University. We also thank the haematologists, radiation, laboratory, pathologists and all other participating department for the sustained scientific collaboration.

Disclosure statement

The authors declared that they have no commercial, proprietary, financial interest or any potential conflicts in the producers or companies described in this manuscript. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Besides, the information has never been presented in any meeting previously.

Additional information

Funding

This work was supported by grants from the National Natural Science Foundation of China (grant number: 81871633), the Beijing Natural Science Foundation (grant number: 7181003) and Beijing Municipal Administration of Hospital Incubating Program (Code: PX2018003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.